EpiBiologics, Inc. — Form D/A
EpiBiologics, Inc. of SAN MATEO, CA, a company, filed a Form D amendment with the SEC on 2024-04-25. The offering totals $73.0M, of which $73.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-04-25
- Form: D/A
- Accession: 0001288320-24-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $73.0M
- Amount sold: $73.0M
- Investors: 15
- Date of first sale: 2022-03-21
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-480390
Issuer
- Name: EpiBiologics, Inc.
- CIK: 0001968158
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 1900 ALAMEDA DE LAS PULGAS, SAN MATEO, CA, 94403
- Phone: (650) 452-3510
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Samuel Bjork | Director | Cambridge, MA |
| Alexandra Cantley | Director | Newton, MA |
| Jason Coloma | Director | AUSTIN, TX |
| Ann Lee-Karlon | Director | San Mateo, CA |
| Seiji Miyahara | Director | San Mateo, CA |
| Mitchell Mutz | Director | Seattle, WA |
| James Wells | Director | Vancouver, A1 |
| Ann Lee-Karlon | Executive Officer | San Mateo, CA |
| Mitchell Mutz | Executive Officer | Seattle, WA |
| Michael Kavanaugh | Director | San Mateo, CA |
| Rami Hannoush | Director | San Mateo, CA |
| Rami Hannoush | Executive Officer | San Mateo, CA |
| Craig Lichtenstein | Executive Officer | San Mateo, CA |
Other filings by this issuer (1)
More